Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics

Zacks11-09

Evolent Health (EVH) reported $621.4 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 21.6%. EPS of $0.04 for the same period compares to $0.30 a year...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482454191?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba","is_english":true,"pubTime":"2024-11-09 04:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482454191","market":"us","top_or_hot":-1,"title":"Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics","media":"Zacks","content":"<div>\n<p>Evolent Health (EVH) reported $621.4 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 21.6%. EPS of $0.04 for the same period compares to $0.30 a year...</p>\n\n<a href=\"https://finance.yahoo.com/news/compared-estimates-evolent-health-evh-203002551.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 04:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/compared-estimates-evolent-health-evh-203002551.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Evolent Health (EVH) reported $621.4 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 21.6%. EPS of $0.04 for the same period compares to $0.30 a year...</p>\n\n<a href=\"https://finance.yahoo.com/news/compared-estimates-evolent-health-evh-203002551.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVH","symbol_name":"Evolent Health Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/compared-estimates-evolent-health-evh-203002551.html","article_id":"2482454191","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482454191","pubTimestamp":1731097802,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Evolent Health  reported $621.4 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 21.6%. EPS of $0.04 for the same period compares to $0.30 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $625.58 million, representing a surprise of -0.67%. The company delivered an EPS surprise of -86.67%, with the consensus EPS estimate being $0.30.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Average PMPM Fees / Revenue per Case - Performance Suite: $20.97 versus the three-ana","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EVH":"Evolent Health Inc"},"translate_title":"与预期相比，Evolent Health(EVH)第三季度收益：关键指标一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVH":1},"content_text":"Evolent Health (EVH) reported $621.4 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 21.6%. EPS of $0.04 for the same period compares to $0.30 a year ago.\nThe reported revenue compares to the Zacks Consensus Estimate of $625.58 million, representing a surprise of -0.67%. The company delivered an EPS surprise of -86.67%, with the consensus EPS estimate being $0.30.\nWhile investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.\nSince these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.\nHere is how Evolent Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: \n\nAverage PMPM Fees / Revenue per Case - Performance Suite: $20.97 versus the three-analyst average estimate of $21.43.\nAverage PMPM Fees / Revenue per Case - Specialty Technology and Services Suite: $0.38 compared to the $0.37 average estimate based on three analysts.\nAverage PMPM Fees / Revenue per Case - Administrative Services: $15.74 versus the three-analyst average estimate of $15.49.\nAverage Lives on Platform / Cases - Cases: 13 thousand compared to the 15.1 thousand average estimate based on three analysts.\nAverage Lives on Platform / Cases - Performance Suite: 6.92 million versus the three-analyst average estimate of 6.88 million.\nAverage Lives on Platform / Cases - Specialty Technology and Services Suite: 74.19 million versus 73.82 million estimated by three analysts on average.\nAverage Lives on Platform / Cases - Administrative Services: 1.26 million compared to the 1.27 million average estimate based on three analysts.\nAverage PMPM Fees / Revenue per Case - Cases: $3,113 versus $2,859.51 estimated by three analysts on average.\nTotal Revenue by product type- Performance Suite: $435.10 million versus $441.93 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +34.4% change.\nTotal Revenue by product type- Cases: $41.43 million versus $43.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.9% change.\nTotal Revenue by product type- Administrative Services: $59.40 million versus the three-analyst average estimate of $58.87 million. The reported number represents a year-over-year change of -13.6%.\nTotal Revenue by product type- Specialty Technology and Services Suite: $85.47 million versus $81.94 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.2% change.\n View all Key Company Metrics for Evolent Health here>>>\n\nShares of Evolent Health have returned -8.3% over the past month versus the Zacks S&P 500 composite's +4.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nEvolent Health, Inc (EVH) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482454191"}